Maria E. Cabanillas

16.9k total citations · 5 hit papers
215 papers, 10.1k citations indexed

About

Maria E. Cabanillas is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Maria E. Cabanillas has authored 215 papers receiving a total of 10.1k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Endocrinology, Diabetes and Metabolism, 89 papers in Oncology and 42 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Maria E. Cabanillas's work include Thyroid Cancer Diagnosis and Treatment (141 papers), Cancer-related Molecular Pathways (36 papers) and BRCA gene mutations in cancer (33 papers). Maria E. Cabanillas is often cited by papers focused on Thyroid Cancer Diagnosis and Treatment (141 papers), Cancer-related Molecular Pathways (36 papers) and BRCA gene mutations in cancer (33 papers). Maria E. Cabanillas collaborates with scholars based in United States, France and Australia. Maria E. Cabanillas's co-authors include Cosimo Durante, David G. McFadden, Naifa L. Busaidy, Mark Zafereo, Ramona Dadu, Steven I. Sherman, Michelle D. Williams, Steven G. Waguespack, Camilo Jiménez and Mouhammed Amir Habra and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Maria E. Cabanillas

198 papers receiving 10.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thyroid cancer

2016 1.1k citations Maria E. Cabanillas et al. profile →
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

2017 607 citations Vivek Subbiah, Maria E. Cabanillas et al. Journal of Clinical Oncology profile →
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

2021 374 citations Keith C. Bible, Maria E. Cabanillas et al. Thyroid profile →
Thyroid Cancer

2024 219 citations Mark Zafereo, Maria E. Cabanillas et al. profile →
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

2022 183 citations Vivek Subbiah, Maria E. Cabanillas et al. profile →

Peers

Countries citing papers authored by Maria E. Cabanillas

Since Specialization

Citations

This map shows the geographic impact of Maria E. Cabanillas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria E. Cabanillas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria E. Cabanillas more than expected).

Fields of papers citing papers by Maria E. Cabanillas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria E. Cabanillas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria E. Cabanillas. The network helps show where Maria E. Cabanillas may publish in the future.

Co-authorship network of co-authors of Maria E. Cabanillas

This figure shows the co-authorship network connecting the top 25 collaborators of Maria E. Cabanillas. A scholar is included among the top collaborators of Maria E. Cabanillas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria E. Cabanillas. Maria E. Cabanillas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer 2025 ·Thyroid ·Maria E. Cabanillas, Naifa L. Busaidy, G. Brandon Gunn, Padmini Iyer, Renata Ferrarotto, Maria Gule-Monroe, Anastasios Maniakas, Michelle D. Williams, Suyu Liu, Bryan Fellman, Michael T. Spiotto, (unknown), (unknown), Anna Lee, Jennifer Wang, Luana Guimarães de Sousa, (unknown), Mark Zafereo, Ramona Dadu	1
2	Advances in Anaplastic Thyroid Cancer Treatment 2025 ·Endocrinology and Metabolism Clinics of North America ·(unknown), Anastasios Maniakas, Maria E. Cabanillas	0
3	Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis 2025 ·Thyroid ·Hamza Salim, Ahmed Msherghi, Kim O. Learned, Mark Zafereo, Jennifer Wang, (unknown), (unknown), (unknown), (unknown), Mimi I. Hu, Maria E. Cabanillas, Naifa L. Busaidy, (unknown), Hussein Tawbi, Jing Li, (unknown), Max Wintermark	0
4	[¹⁸F]-FDG Uptake as a Marker of Residual Anaplastic and Poorly Differentiated Thyroid Carcinoma followingBRAF-Targeted Therapy 2024 ·American Journal of Neuroradiology ·(unknown), Kim O. Learned, (unknown), Jennifer Wang, Xiao Zhao, S. Mohsen Hosseini, Anastasios Maniakas, Maria E. Cabanillas, Naifa L. Busaidy, Ramona Dadu, Priyanka Iyer, Mark Zafereo, Alexander Khalaf	0
5	Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC). 2024 ·Journal of Clinical Oncology ·Maria E. Cabanillas, (unknown), Marcia S. Brose, Ray McDermott, (unknown), Jessica R. Bauman, Michela Casanova, Shivaani Kummar, Se‐Hoon Lee, Serge Leyvraz, Do‐Youn Oh, Lin Shen, (unknown), (unknown), Chiara Mussi, David S. Hong, Alexander Drilon, Steven G. Waguespack	4
6	Next-Generation Sequencing in Sporadic Medullary Thyroid Cancer Patients: Mutation Profile and Disease Aggressiveness 2024 ·Journal of the Endocrine Society ·(unknown), Mimi I. Hu, Yi‐Ju Chiang, Paul H. Graham, Sarah B. Fisher, Julie Ann Sosa, Nancy D. Perrier, (unknown), Vijaykumar Holla, Ramona Dadu, Naifa L. Busaidy, Steven I. Sherman, Maria E. Cabanillas, Steven G. Waguespack, Mark Zafereo, Elizabeth Grubbs	8
7	Cobimetinib plus atezolizumab for RAS and NF1/2-mutated poorly differentiated thyroid carcinoma. 2024 ·Journal of Clinical Oncology ·(unknown), Ramona Dadu, Naifa L. Busaidy, Renata Ferrarotto, Maria Gule-Monroe, Suyu Liu, Bryan Fellman, Michelle D. Williams, (unknown), Jennifer Wang, Charles Lu, Matthew S. Ning, Brian McKinley, Scott E. Woodman, Dzifa Y. Duose, Maria E. Cabanillas, G. Brandon Gunn	3
8	BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study 2023 ·npj Precision Oncology ·Blessie Elizabeth Nelson, Jason Roszik, Filip Jankú, David S. Hong, Shumei Kato, Aung Naing, Sarina A. Piha‐Paul, Siqing Fu, Apostolia M. Tsimberidou, Maria E. Cabanillas, Naifa L. Busaidy, Milind Javle, Lauren A. Byers, John V. Heymach, Funda Meric‐Bernstam, Vivek Subbiah	16
9	Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma 2022 ·JCO Precision Oncology ·Jennifer Wang, (unknown), Xu Li, Maitrayee Goswami, Xiao Zhao, Gilbert J. Cote, Wenyi Wang, Priyanka Iyer, Ramona Dadu, Naifa L. Busaidy, Stephen Y. Lai, Neil D. Gross, Renata Ferrarotto, Charles Lu, G. Brandon Gunn, Michelle D. Williams, Mark J. Routbort, Mark Zafereo, Maria E. Cabanillas	45
10	Immune Checkpoint Inhibitor Induced Multi Organ Sarcoid-Like Reaction 2022 ·Journal of the American Society of Nephrology ·(unknown), Amanda Tchakarov, Maria E. Cabanillas, Ala Abudayyeh	0
11	Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid 2021 ·JMIR Formative Research ·(unknown), Aubri Hoffman, (unknown), Maria E. Cabanillas, Julie Ann Sosa, Steven G. Waguespack, Mark Zafereo, Mimi I. Hu, Elizabeth Grubbs	5
12	Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer 2021 ·Journal of Clinical Oncology ·Lori J. Wirth, Marcia S. Brose, Eric J. Sherman, Lisa Licitra, Martin Schlumberger, Steven I. Sherman, Keith C. Bible, Bruce Robinson, Patrice Rodien, Yann Godbert, Christelle de la Fouchardière, Kate Newbold, Christopher M. Nutting, Soamnauth Misir, Ran Xie, (unknown), (unknown), Maria E. Cabanillas	83
13	Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma 2021 ·Thyroid ·Yu Qin, Jennifer Wang, Ying Wang, Priyanka Iyer, Gilbert J. Cote, Naifa L. Busaidy, Ramona Dadu, Mark Zafereo, Michelle D. Williams, Renata Ferrarotto, G. Brandon Gunn, Peng Wei, Keyur P. Patel, Marie‐Claude Hofmann, Maria E. Cabanillas	34
14	Distinguishing Recurrent Thyroid Cancer from Residual Nonmalignant Thyroid Tissue Using Multiphasic Multidetector CT 2020 ·American Journal of Neuroradiology ·J. Matthew Debnam, Nandita Guha‐Thakurta, Jia Sun, Wei Wei, Mark Zafereo, Maria E. Cabanillas, (unknown), Dawid Schellingerhout	5
15	Spine Stereotactic Radiosurgery for Metastatic Thyroid Cancer: A Single-Institution Experience 2019 ·International Journal of Radiation OncologyBiologyPhysics ·David Boyce-Fappiano, Todd A. Pezzi, Olsi Gjyshi, M. Bernstein, Pamela K. Allen, Maria E. Cabanillas, Behrang Amini, Claudio E. Tatsui, Laurence D. Rhines, (unknown), D.N. Yeboa, Andrew J. Bishop, J. Li, Amol J. Ghia	3
16	Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy 2018 ·Molecular Cancer Therapeutics ·Hui Chen, Rajyalakshmi Luthra, Mark J. Routbort, Keyur P. Patel, Maria E. Cabanillas, Russell R. Broaddus, Michelle D. Williams	70
17	Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma 2017 ·Thyroid ·Priyanka Iyer, Ramona Dadu, Renata Ferrarotto, Naifa L. Busaidy, Mouhammed Amir Habra, Mark Zafereo, Neil D. Gross, Kenneth R. Hess, Maria Gule-Monroe, Michelle D. Williams, Maria E. Cabanillas	88
18	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells 2016 ·Clinical Cancer Research ·Chad Tang, James W. Welsh, Patricia M. de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel D. Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing, David S. Hong	251
19	A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer 2015 ·Clinical Cancer Research ·Martin Schlumberger, Barbara Jarząb, Maria E. Cabanillas, Bruce Robinson, Furio Pacini, Douglas W. Ball, Judith C. McCaffrey, Kate Newbold, Roger Allison, Renato Martins, Lisa Licitra, Manisha H. Shah, Donald Bodenner, Rossella Elisei, Lynn A. Burmeister, Yasuhiro Funahashi, Min Ren, James P. O'Brien, Steven I. Sherman	184
20	Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas 2012 ·The Journal of Clinical Endocrinology & Metabolism ·Montserrat Ayala‐Ramirez, C. Chougnet, Mouhammed Amir Habra, J. Lynn Palmer, Sophie Leboulleux, Maria E. Cabanillas, Caroline Caramella, Pete Anderson, Abir Al Ghuzlan, Steven G. Waguespack, Désirèe Deandreis, Éric Baudin, Camilo Jiménez	144

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact